Comparison Overview

Lincoln Pharmaceuticals Ltd

VS

Bristol Myers Squibb

Lincoln Pharmaceuticals Ltd

Science City Road, Ahmedabad, Gujarat, 380060, IN
Last Update: 2025-05-06 (UTC)
View Profile
Between 750 and 799
https://www.lincolnpharma.com

Lincoln is proud of its manufacturing capabilities. We are really distinct and powerful when it comes to the production capacity. Set up in the year 1979, the manufacturing facility of Lincoln is based at Khatraj, Gujarat sharing the same dais as with the international standards. Another manufacturing setup at Mehsana, Gujarat and Head Office in Ahemedabad city of Gujarat. There are global standards and norms which a manufacturing lab should scan through and we ensure that our processes are in compliance with WHO-cGMP norms. Our lab has been given ISO 9001:2015 certifications; thoroughly highlighting Lincoln’s dedication in direction of high quality and safety. These certifications and achievement has added new feather to out hat. With these achievements, we also furthermore plan to expand the capabilities in the US and UK markets making the presence global and more rewarding.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 807
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Bristol Myers Squibb

3401 Princeton Pike, None, Lawrence Township, NJ, US, 08648
Last Update: 2025-08-05 (UTC)
Between 800 and 849
http://www.bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 38,467
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
1

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/lincoln-pharmaceuticals-ltd.jpeg
Lincoln Pharmaceuticals Ltd
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/bristol-myers-squibb.jpeg
Bristol Myers Squibb
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Lincoln Pharmaceuticals Ltd
100%
Compliance Rate
0/4 Standards Verified
Bristol Myers Squibb
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Lincoln Pharmaceuticals Ltd in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Bristol Myers Squibb in 2025.

Incident History — Lincoln Pharmaceuticals Ltd (X = Date, Y = Severity)

Lincoln Pharmaceuticals Ltd cyber incidents detection timeline including parent company and subsidiaries

Incident History — Bristol Myers Squibb (X = Date, Y = Severity)

Bristol Myers Squibb cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/lincoln-pharmaceuticals-ltd.jpeg
Lincoln Pharmaceuticals Ltd
Incidents

No Incident

https://images.rankiteo.com/companyimages/bristol-myers-squibb.jpeg
Bristol Myers Squibb
Incidents

Date Detected: 5/2023
Type:Cyber Attack
Attack Vector: Malware
Blog: Blog

FAQ

Bristol Myers Squibb company demonstrates a stronger AI Cybersecurity Score compared to Lincoln Pharmaceuticals Ltd company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Bristol Myers Squibb company has historically faced a number of disclosed cyber incidents, whereas Lincoln Pharmaceuticals Ltd company has not reported any.

In the current year, Bristol Myers Squibb company and Lincoln Pharmaceuticals Ltd company have not reported any cyber incidents.

Neither Bristol Myers Squibb company nor Lincoln Pharmaceuticals Ltd company has reported experiencing a ransomware attack publicly.

Neither Bristol Myers Squibb company nor Lincoln Pharmaceuticals Ltd company has reported experiencing a data breach publicly.

Bristol Myers Squibb company has reported targeted cyberattacks, while Lincoln Pharmaceuticals Ltd company has not reported such incidents publicly.

Neither Lincoln Pharmaceuticals Ltd company nor Bristol Myers Squibb company has reported experiencing or disclosing vulnerabilities publicly.

Neither Lincoln Pharmaceuticals Ltd nor Bristol Myers Squibb holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Lincoln Pharmaceuticals Ltd company nor Bristol Myers Squibb company has publicly disclosed detailed information about the number of their subsidiaries.

Bristol Myers Squibb company employs more people globally than Lincoln Pharmaceuticals Ltd company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Lincoln Pharmaceuticals Ltd nor Bristol Myers Squibb holds SOC 2 Type 1 certification.

Neither Lincoln Pharmaceuticals Ltd nor Bristol Myers Squibb holds SOC 2 Type 2 certification.

Neither Lincoln Pharmaceuticals Ltd nor Bristol Myers Squibb holds ISO 27001 certification.

Neither Lincoln Pharmaceuticals Ltd nor Bristol Myers Squibb holds PCI DSS certification.

Neither Lincoln Pharmaceuticals Ltd nor Bristol Myers Squibb holds HIPAA certification.

Neither Lincoln Pharmaceuticals Ltd nor Bristol Myers Squibb holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
References
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References